Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.59 |
| ▸ | VCP | P55072 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | TLR4 | O00206 | 3/20 | 0.54 |
| ▸ | TLR2 | O60603 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | GALR2 | O43603 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334578 | 1.00 | FBP1 (0.70) | FBP1PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL15514658 | 0.90 | FBP1 (0.62) | FBP1PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL15503187 | 0.90 | FBP1 (0.62) | FBP1PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL23684551 | 0.88 | FBP1 (0.60) | FBP1PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL31287227 | 0.82 | FBP1 (1.00) | FBP1VCPTLR4TLR2 | |
| SCHEMBL792987 | 0.82 | FBP1 (1.00) | FBP1VCPTLR4TLR2 | |
| SCHEMBL8765211 | 0.82 | FBP1 (1.00) | FBP1VCPTLR4TLR2 | |
| SCHEMBL278627 | 0.82 | FBP1 (1.00) | FBP1VCPTLR4TLR2 | |
| SCHEMBL491095 | 0.81 | FBP1 (1.00) | FBP1VCPTLR4TLR2EGFR | |
| SCHEMBL491094 | 0.81 | FBP1 (1.00) | FBP1VCPTLR4TLR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108863804-A | A kind of new preparation process of 3,5- dimethoxy-beta-nitrostyrene | 上海华堇生物技术有限责任公司 | 2018-11-23 | — | — | CN | claimed |
| CN-108863804-A | A kind of new preparation process of 3,5- dimethoxy-beta-nitrostyrene | 上海华堇生物技术有限责任公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108863804-A | A kind of new preparation process of 3,5- dimethoxy-beta-nitrostyrene | 上海华堇生物技术有限责任公司 | 2018-11-23 | — | — | CN | disclosed |
| US-8097656-B2 | Nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof | Dominion Pharmakine S.L (ES) | 2012-01-17 | — | — | US | disclosed |
| US-20110060038-A1 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | DOMINION PHARMAKINE S.L. (ES) | 2011-03-10 | — | — | US | disclosed |
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | UNIVERSIDAD DEL PAIS VASCO (ES) | 2009-12-03 | — | — | US | disclosed |
| EP-1379523-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
| US-4920221-A | CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | PFIZER INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0090516-B1 | SUBSTITUTED HEXAHYDROPYRROLO(1,2-A)-QUINOLINE, HEXAHYDRO-1H-PYRIDO(1,2-A)-QUINOLINE, HEXAHYDROBENZO(3)INDENE AND OCTAHYDROPHENANTHRENE CNS AGENTS | PFIZER INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| WO-1988003147-A1 | SELECTED N6-SUBSTITUTED ADENOSINES HAVING SELECTIVE A2 BINDING ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1988-05-05 | — | — | WO | disclosed |
| US-4642373-A | Substituted dodecahydrotripheylenes, and decahydropyrrolo[1,2-f]phenanthridines as CNS agents | PFIZER INC. (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0090526-B1 | SUBSTITUTED DODECAHYDROTRIPHENYLENES, DECAHYDRO-1H-CYCLOPENTA(1)PHENANTHRENES, DECAHYDRO-1H-PYRIDO(1,2-F)PHENANTHRIDINES AND DECAHYDROPYRROLO(1,2-F)PHENANTHRIDINES AS CNS AGENTS | PFIZER INC. (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4576964-A | ANALGESICS, ANTIEMETICS | PFIZER INC. (US) | 1986-03-18 | — | — | US | disclosed |
| US-4476131-A | ANTIEMETICS, ANALGESICS | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| US-4473704-A | ANALGESICS, ANTIEMETICS | PFIZER INC. (US) | 1984-09-25 | — | — | US | disclosed |
| EP-0090526-A1 | Substituted dodecahydrotriphenylenes, decahydro-1H-cyclopenta(1)phenanthrenes, decahydro-1H-pyrido(1,2-f)phenanthridines and decahydropyrrolo(1,2-f)phenanthridines as CNS agents | PFIZER INC. (US) | 1983-10-05 | — | — | EP | disclosed |
| EP-0090516-A1 | Substituted hexahydropyrrolo(1,2-a)-quinoline, hexahydro-1H-pyrido(1,2-a)-quinoline, hexahydrobenzo(3)indene and octahydrophenanthrene CNS agents | PFIZER INC. (US) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | TNNI3, TNNT2, INMT | FBP1 1591/4885PTGS2 141/4885PTGS1 79/4885 |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | FBP1 1952/4885PTGS2 356/4885PTGS1 282/4885 |
| US-20110060038-A1 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | TNNI3, TNNT2, NOS2 | FBP1 1384/4885PTGS2 145/4885PTGS1 84/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | FBP1 1699/4885PTGS2 180/4885PTGS1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.